JP2016518324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518324A5 JP2016518324A5 JP2016501372A JP2016501372A JP2016518324A5 JP 2016518324 A5 JP2016518324 A5 JP 2016518324A5 JP 2016501372 A JP2016501372 A JP 2016501372A JP 2016501372 A JP2016501372 A JP 2016501372A JP 2016518324 A5 JP2016518324 A5 JP 2016518324A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- aryl
- pharmaceutically acceptable
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 6
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 6
- -1 substituted Chemical class 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 2
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000005325 aryloxy aryl group Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- CMONQYKXNSYVBH-UHFFFAOYSA-N 3-[4-[bis(2-methylpropyl)amino]-3-[(3-methyl-1,2-oxazol-5-yl)carbamoylamino]phenyl]butanoic acid Chemical compound CC(C)CN(CC(C)C)C1=CC=C(C(C)CC(O)=O)C=C1NC(=O)NC1=CC(C)=NO1 CMONQYKXNSYVBH-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000016680 Dioxygenases Human genes 0.000 claims 1
- 108010028143 Dioxygenases Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000003106 haloaryl group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 229960004854 viral vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787939P | 2013-03-15 | 2013-03-15 | |
| US61/787,939 | 2013-03-15 | ||
| PCT/US2014/023877 WO2014150646A1 (en) | 2013-03-15 | 2014-03-12 | Ido inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016518324A JP2016518324A (ja) | 2016-06-23 |
| JP2016518324A5 true JP2016518324A5 (enExample) | 2017-03-02 |
| JP6313415B2 JP6313415B2 (ja) | 2018-04-18 |
Family
ID=50391513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501372A Active JP6313415B2 (ja) | 2013-03-15 | 2014-03-12 | Ｉｄｏ阻害剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9624188B2 (enExample) |
| EP (1) | EP2970114B1 (enExample) |
| JP (1) | JP6313415B2 (enExample) |
| KR (1) | KR20150129010A (enExample) |
| CN (1) | CN105324362B (enExample) |
| AU (1) | AU2014235816B2 (enExample) |
| BR (1) | BR112015022462A8 (enExample) |
| CA (1) | CA2907178A1 (enExample) |
| EA (1) | EA028424B1 (enExample) |
| ES (1) | ES2733546T3 (enExample) |
| HK (1) | HK1220442A1 (enExample) |
| IL (1) | IL241321A0 (enExample) |
| MA (1) | MA38483A1 (enExample) |
| MX (1) | MX2015012056A (enExample) |
| PE (1) | PE20151594A1 (enExample) |
| PH (1) | PH12015502028A1 (enExample) |
| SG (1) | SG11201506920QA (enExample) |
| WO (1) | WO2014150646A1 (enExample) |
| ZA (1) | ZA201506796B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| BR112015021999A8 (pt) * | 2013-03-15 | 2019-12-03 | Bristol Myers Squibb Co | inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase |
| JP2016528197A (ja) | 2013-07-01 | 2016-09-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｉｄｏ阻害剤 |
| WO2015006520A1 (en) * | 2013-07-11 | 2015-01-15 | Bristol-Myers Squibb Company | Ido inhibitors |
| RU2742241C2 (ru) | 2015-03-23 | 2021-02-04 | Джоунс Терапьютикс, Инк. | Антитела к icos |
| US10399933B2 (en) * | 2015-04-03 | 2019-09-03 | Bristol-Myers Squibb Company | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer |
| CN107922353A (zh) * | 2015-06-26 | 2018-04-17 | 百时美施贵宝公司 | Ido抑制剂 |
| CN116196426A (zh) | 2015-07-16 | 2023-06-02 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| MX2018001014A (es) | 2015-07-24 | 2018-05-23 | Newlink Genetics Corp | Sales y profarmacos de 1-metil-d-triptofano. |
| CN108368049A (zh) * | 2015-09-24 | 2018-08-03 | 葛兰素史克知识产权开发有限公司 | 吲哚胺2,3-双加氧酶的调节剂 |
| CN108601767A (zh) * | 2015-10-05 | 2018-09-28 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法 |
| JP2018534927A (ja) | 2015-10-22 | 2018-11-29 | ジョンス セラピューティクス， インコーポレイテッド | Ｉｃｏｓ発現を決定する遺伝子シグネチャー |
| EP3414224B1 (en) * | 2016-02-09 | 2022-03-23 | InventisBio LLC | Inhibitor of indoleamine-2,3-dioxygenase (ido) |
| EP3416725A1 (en) | 2016-02-19 | 2018-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity |
| BR112018071602B1 (pt) * | 2016-04-29 | 2024-02-27 | Iomet Pharma Ltd. | Compostos de imidazopiridina substituídos, sua composição e seus usos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3- dioxigenase |
| CA3023034A1 (en) * | 2016-05-12 | 2017-11-16 | Glaxosmithkline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| AR108586A1 (es) | 2016-06-10 | 2018-09-05 | Lilly Co Eli | Compuestos de 2,3-dihidro-1h-indol |
| AU2017315572B2 (en) * | 2016-08-23 | 2021-07-15 | Beijing Innocare Pharma Tech Co., Ltd. | Fused heterocyclic derivative, preparation method therefor and medical use thereof |
| CN109952300B (zh) | 2016-09-24 | 2022-01-18 | 百济神州有限公司 | 5或8-取代的咪唑并[1,5-a]吡啶 |
| AU2017343780B2 (en) | 2016-10-13 | 2023-08-31 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
| US10654929B2 (en) | 2016-11-02 | 2020-05-19 | Jounce Therapeutics, Inc. | Antibodies to PD-1 and uses thereof |
| US11672771B2 (en) | 2016-11-04 | 2023-06-13 | Aximmune, Inc. | Beta-alethine, immune modulators, and uses thereof |
| EP3558978A1 (en) | 2016-12-20 | 2019-10-30 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| PE20191541A1 (es) | 2016-12-22 | 2019-10-23 | Calithera Biosciences Inc | Composiciones y metodos para inhibir la accion de la arginasa |
| JP2020506895A (ja) | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
| WO2018187191A1 (en) | 2017-04-03 | 2018-10-11 | Jounce Therapeutics, Inc | Compositions and methods for the treatment of cancer |
| US11319295B2 (en) | 2017-10-09 | 2022-05-03 | Merck Sharp & Dohme Corp. | Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| CN109836356B (zh) * | 2017-11-24 | 2022-03-08 | 沈阳化工研究院有限公司 | 一种芳甲醚衍生物及其应用 |
| EP3728318A2 (en) | 2017-12-22 | 2020-10-28 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
| US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| CN111587116A (zh) | 2018-01-05 | 2020-08-25 | 迪克纳制药公司 | 降低β-连环蛋白和IDO表达以加强免疫疗法 |
| CN112703012A (zh) | 2018-05-14 | 2021-04-23 | 震动疗法公司 | 治疗癌症的方法 |
| US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| WO2020023355A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US12145927B2 (en) | 2018-07-23 | 2024-11-19 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US20210353750A1 (en) | 2018-10-18 | 2021-11-18 | Jounce Therapeutics, Inc. | Methods of Treating Cancer |
| WO2020086802A1 (en) | 2018-10-24 | 2020-04-30 | Jounce Therapeutics, Inc. | Methods and compositions for the treatment of cancer and infectious diseases |
| WO2020086943A1 (en) | 2018-10-26 | 2020-04-30 | Jounce Therapeutics, Inc. | Methods of treating cancer |
| WO2020185739A1 (en) | 2019-03-11 | 2020-09-17 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
| US20220378909A1 (en) | 2019-11-05 | 2022-12-01 | Jounce Therapeutics, Inc. | Methods of Treating Cancer with Anti-PD-1 Antibodies |
| EP4041402A1 (en) | 2019-11-12 | 2022-08-17 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing ido antagonist prodrugs useful in the treatment of cancer and methods thereof |
| WO2021102618A1 (en) * | 2019-11-25 | 2021-06-03 | InventisBio Co., Ltd. | Novel salts of indoleamine 2,3-dioxygenase inhibitors |
| WO2021146303A1 (en) | 2020-01-13 | 2021-07-22 | Jounce Therapeutics, Inc. | Methods for the treatment of cancer |
| CN111153846B (zh) * | 2020-01-17 | 2021-08-31 | 中国药科大学 | 吡咯类化合物、其制备方法和药物组合物与用途 |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| US20240091202A1 (en) | 2021-03-05 | 2024-03-21 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
| WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5447957A (en) * | 1994-06-02 | 1995-09-05 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
| JP4618845B2 (ja) * | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体 |
| AU2002222573A1 (en) * | 2000-12-05 | 2002-06-18 | Kyorin Pharmaceutical Co. Ltd. | Substituted carboxylic acid derivatives |
| US7312214B2 (en) | 2002-05-10 | 2007-12-25 | Bristol-Myers Squibb Company | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors |
| US7056925B2 (en) * | 2002-08-13 | 2006-06-06 | Abbott Laboratories | Urea kinase inhibitors |
| US20040034038A1 (en) * | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
| KR20070032648A (ko) * | 2004-05-12 | 2007-03-22 | 브리스톨-마이어스 스큅 컴퍼니 | 혈전 상태의 치료에 유용한 ｐ２ｙ１ 수용체의 우레아길항제 |
| US20090239841A1 (en) * | 2004-10-27 | 2009-09-24 | Hutchison Alan J | Diaryl Ureas as CB1 Antagonists |
| GB0613674D0 (en) * | 2006-07-10 | 2006-08-16 | Proskelia Sas | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
| CN102083429B (zh) * | 2008-04-24 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| BR112015021999A8 (pt) | 2013-03-15 | 2019-12-03 | Bristol Myers Squibb Co | inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase |
-
2014
- 2014-03-12 MA MA38483A patent/MA38483A1/fr unknown
- 2014-03-12 AU AU2014235816A patent/AU2014235816B2/en not_active Ceased
- 2014-03-12 HK HK16108593.6A patent/HK1220442A1/zh unknown
- 2014-03-12 BR BR112015022462A patent/BR112015022462A8/pt not_active Application Discontinuation
- 2014-03-12 CN CN201480028214.8A patent/CN105324362B/zh not_active Expired - Fee Related
- 2014-03-12 ES ES14714106T patent/ES2733546T3/es active Active
- 2014-03-12 JP JP2016501372A patent/JP6313415B2/ja active Active
- 2014-03-12 SG SG11201506920QA patent/SG11201506920QA/en unknown
- 2014-03-12 MX MX2015012056A patent/MX2015012056A/es unknown
- 2014-03-12 EA EA201591823A patent/EA028424B1/ru not_active IP Right Cessation
- 2014-03-12 CA CA2907178A patent/CA2907178A1/en not_active Abandoned
- 2014-03-12 WO PCT/US2014/023877 patent/WO2014150646A1/en not_active Ceased
- 2014-03-12 US US14/775,976 patent/US9624188B2/en active Active
- 2014-03-12 KR KR1020157029305A patent/KR20150129010A/ko not_active Ceased
- 2014-03-12 EP EP14714106.3A patent/EP2970114B1/en active Active
- 2014-03-12 PE PE2015001950A patent/PE20151594A1/es not_active Application Discontinuation
-
2015
- 2015-09-08 IL IL241321A patent/IL241321A0/en unknown
- 2015-09-10 PH PH12015502028A patent/PH12015502028A1/en unknown
- 2015-09-14 ZA ZA2015/06796A patent/ZA201506796B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518324A5 (enExample) | ||
| JP2016519653A5 (enExample) | ||
| JP2016528197A5 (enExample) | ||
| JP2016530283A5 (enExample) | ||
| JP2016523974A5 (enExample) | ||
| JP2018515438A5 (enExample) | ||
| JP2018516238A5 (enExample) | ||
| JP2013056930A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2016513661A5 (enExample) | ||
| JP2016501221A5 (enExample) | ||
| JP2017504635A5 (enExample) | ||
| JP2014139226A5 (enExample) | ||
| JP2009541223A5 (enExample) | ||
| JP2015511609A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2015509975A5 (enExample) | ||
| NZ629432A (en) | Heterocyclyl compounds as mek inhibitors | |
| JP2020507589A5 (enExample) | ||
| RU2013109132A (ru) | Химические соединения | |
| JP2014518544A5 (enExample) | ||
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| JP2017531619A5 (enExample) |